Mobile

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial of 48 Weeks of GS-9190 in Combination with Peginterferon Alfa 2a (Pegasys®) and Ribavirin (Copegus®) in Previously Untreated Subjects with...

Mise à jour : Il y a 4 ans
Référence : EUCTR2009-013442-86

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial of 48 Weeks of GS-9190 in Combination with Peginterferon Alfa 2a (Pegasys®) and Ribavirin (Copegus®) in Previously Untreated Subjects with Genotype-1 Chronic Hepatitis C Virus (HCV) Infection

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To compare the antiviral efficacy (sustained virologic response; SVR) of 48 weeks of GS-9190 versus placebo when administered in combination with 48 weeks of peginterferon alfa 2a (PEG) and ribavirin (RIBA)

Critère d'inclusion

  • Chronic hepatitis C virus infection

Liens